Compare NISN & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NISN | ALLR |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4M | 20.2M |
| IPO Year | 2016 | N/A |
| Metric | NISN | ALLR |
|---|---|---|
| Price | $3.60 | $1.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.25 |
| AVG Volume (30 Days) | 15.1K | ★ 208.7K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | ★ $340,219,546.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.58 | ★ N/A |
| Revenue Growth | ★ 8.05 | N/A |
| 52 Week Low | $3.22 | $0.61 |
| 52 Week High | $9.33 | $2.35 |
| Indicator | NISN | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 40.00 | 53.52 |
| Support Level | $3.58 | $0.99 |
| Resistance Level | $3.82 | $1.17 |
| Average True Range (ATR) | 0.20 | 0.10 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 0.00 | 87.41 |
NiSun International Enterprise Development Group Co Ltd is a provider of supply chain solutions and integrated financial services. Nisun is dedicated to providing professional supply chain solutions to Chinese and foreign enterprises and financial institutions. Through its subsidiaries, it is engaged in delivering supply chain solutions, and supply chain trading services to its customers across different industries. The company also provides financial solutions to small and mid-sized enterprises within the supply chain ecosystem. Using its fintech platforms, it provides various financing options, including supply chain financing, trade financing, and receivables financing. Geographically, its operations are predominantly focused on markets within the People's Republic of China.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.